NICE Approves MabThera(R) (Rituximab) As Maintenance Therapy For Patients With Follicular Non-Hodgkin Lymphoma

The National Institute for Health and Clinical Excellence (NICE) issued final guidance recommending the use of MabThera(R) (rituximab), as a maintenance therapy for patients with relapsed/refractory follicular non-Hodgkin lymphoma (NHL) responding to induction therapy with chemotherapy with or without rituximab.

More: continued here

Filed under: Lymphoma / Leukemia on March 3rd, 2008